The management of imatinib-associated severe skin rash in gastrointestinal stromal tumor: desensitization therapy and pharmacogenetic investigation

A recent study looked at personalized desensitization therapy for imatinib-associated severe skin rash in patients with GIST. This approach, involving temporary imatinib cessation, systemic steroids, and therapeutic drug monitoring-assisted dose escalation, enabled 92.6% of patients to successfully resume treatment. The study also identified a genetic variant (IL-6R rs4129267) potentially involved in rash pathogenesis.